Phase-I, AZD5363 in monotherapy, in multiple advanced solid tumors including liver cancer (NCT01895946): safe and tolerable, no data on antitumor responsePhase-I including multiple solid tumors harboring AKT mutations (NCT02465060). Here, AKT1 is linked to liver cancer.